Clinical trials: Lung Malignancy
Lung Cancer
Concomitant Tracheostomy and Lung Resection
This protocol has been designed to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients.
- Trial name
- NCT01053624
- Testing
- Tracheostomy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Clermont-Ferrand
NSCLC
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
This study is a prospective, multicenter, real-world study to investigate the efficacy and safety of bevacizumab plus epidermal growth factor (EGFR) Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB/IV EGFR-mutant…
- Trial name
- BELLA (NCT04575415)
- Testing
- Bevacizumab, Erlotinib, Gefitinib
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Guangdong Association of Clinical Trials
Immunosuppression, Cancer
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due…
- Conditions
- Immunosuppression, Cancer, COVID-19, Other Complication of Kidney Transplant
- Trial name
- SOROCOV (NCT04834089)
- Testing
- AntiSARS-CoV-2 Serum
- Where
- 2 sites in Brazil
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and…
- Trial name
- NCT02364999
- Testing
- Bevacizumab-Pfizer, Bevacizumab-EU, Paclitaxel
- Where
- 263 sites in United States, Australia and 25 more
- Volunteers
- 719 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
Lung Tumour Volume Database
The main aim is to determine, in patients with locoregional, non-small cell lung cancer (NSCLC) treated by definitive radiotherapy, the influence on survival of the volume of primary tumour, as measured from CT imaging, after…
- Trial name
- NCT00351598
- Testing
- Definitive Radiotherapy
- Where
- 15 sites in Australia, New Zealand and 1 more
- Volunteers
- 531 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Small Cell Lung Cancer
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed…
- Trial name
- AK112-311 (NCT07010263)
- Testing
- AK112
- Where
- 53 sites in China
- Volunteers
- 560 people
- Sponsor
- Akeso
Non Small Cell Lung Cancer
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
This is single-arm, open-label study design. Patients will receive brigatinib until disease progression, unacceptable toxicity, withdrawal of consent, of death.
- Trial name
- NCT04074993
- Testing
- Brigatinib
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- JI-YOUN HAN
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
- Trial name
- FORTIS-M (NCT00707304)
- Testing
- Talactoferrin
- Where
- 189 sites in United States, Australia and 21 more
- Volunteers
- 742 people
- Sponsor
- Agennix
Lung Cancer
Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer
We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.
- Trial name
- NCT05742204
- Testing
- Plasma protein biomarker analysis
- Where
- China
- Volunteers
- 3,700 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ewing Sarcoma, Myxoid Liposarcoma
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination…
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT03600649
- Testing
- Seclidemstat, Cyclophosphamide, Topotecan
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Lung Cancer
Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules
Lung cancer screening trials using low-dose chest CT scans have shown a significant reduction of cancer related mortality in subjects at high risk of lung cancer.
- Trial name
- NODU-MR (NCT06825078)
- Testing
- multiparametric MRI
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Adenocarcinoma of the Lung
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
This study is a single arm, open label, national multicenter study, to explore the efficacy and safety of the combination of Camrelizumab, apatinib and albumin paclitaxel in advanced untreated EGFR Wild Type and ALK-negative Lung…
- Trial name
- NCT04459078
- Testing
- Camrelizumab, Albumin Paclitacxel, Apatinib
- Where
- 3 sites in China
- Volunteers
- 63 people
- Sponsor
- Hunan Cancer Hospital
Non Small Cell Lung Cancer
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
- Trial name
- NCT07070440
- Testing
- DZD6008, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Dizal Pharmaceuticals
Small Cell Lung Carcinoma
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Cyclic, 5-day calorie restriction is a safe metabolic intervention when combined with standard therapies in cancer patients, favorably reshaping peripheral blood and intratumor metabolism and immunity in a way that may improve…
- Trial name
- FASTIMMUNE (NCT05703997)
- Testing
- Cyclic, 5-day calorie restriction, Atezolizumab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hilus Pulmonary Neoplasms
Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for Hilus Pumonis Neoplasms.
- Trial name
- IRE (NCT02430597)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04630015
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer, Non-Small-Cell Lung Cancer
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
This study will evaluate feasibility and acceptability of providing the Dignity Therapy/Life Plan intervention to pancreatic or advanced lung cancer patients presenting for treatment in the outpatient medical oncology setting.
- Trial name
- NCT02132325
- Testing
- Dignity Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer
Stereotactic Precision And Conventional Radiotherapy Evaluation
A randomized phase II study for medically inoperable stage I non-small cell lung cancer where stereotactic body radiotherapy in three fractions to 66 Gy is compared with conventionally fractionated radiotherapy to 70 Gy in 35…
- Trial name
- SPACE (NCT01920789)
- Testing
- Stereotactic radiotherapy, Conventionally fractionated radiotherapy
- Volunteers
- 102 people
- Sponsor
- Ass. Prof. Jan Nyman
Lung Cancer
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
The goal of phase 1 of this clinical research study is to find the highest dose of DOTAP:Chol-TUSC2 that can be safely given in combination with Tarceva (erlotinib hydrochloride) to patients with NSCLC.
- Trial name
- NCT01455389
- Testing
- DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Genprex, Inc.